A targeted antidote for reversal of direct factor Xa (FXa) inhibitors is now available for clinical
use in the United States, but it is costly and has limited availability. In a systematic review …

Importance Intracerebral hemorrhage (ICH) is the most devastating adverse event in
patients receiving oral anticoagulation. There is only sparse evidence regarding ICH related …

Importance Although the use of factor Xa (FXa) inhibitors has increased substantially over
the past decade, there are limited data on characteristics and outcomes of FXa inhibitor …

Background: To determine whether the use of oral antithrombotic agents before the onset of
intracerebral hemorrhage (ICH) affects hematoma features and early patient outcome …

There are limited data on the frequency of hematoma expansion with DOACs. In a
prospective study that enrolled 61 DOAC-treated patients presenting with ICH within 24 …

Importance Although use of oral anticoagulants (OACs) is increasing, there is a substantial
lack of data on how to treat OAC-associated intracerebral hemorrhage (ICH). Objective To …

Objective To obtain precise estimates of age, haematoma volume, secondary haematoma
expansion (HE) and mortality for patients with intracerebral haemorrhage (ICH) taking oral …

Background Intracerebral hemorrhage is the least treatable form of stroke and is associated
with high mortality. Among patients who undergo computed tomography (CT) within three …

Hematoma growth is common in intracerebral hemorrhage (ICH) and is associated with a
poor outcome for patients. To evaluate the efficacy and safety of recombinant activated factor …

Background Intracerebral hemorrhage is the least treatable form of stroke. We performed
this phase 3 trial to confirm a previous study in which recombinant activated factor VII …